Patent details
300816
Product Name:
Alemtuzumab
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300816
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2066352
Status:
Refused Art. 10 of the EC Regulations
Application number:
300816
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/13/869
Marketing Authorization Type:
EEA
Marketing Authorization Date:
16/09/2013
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
31/05/2016
First Marketing Authorization date:
16/09/2013
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
03/06/2016
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
21/10/2020
Applicant/holder
From:
03/06/2016
Name:
Genzyme Corporation
Address:
500 Kendall Street, 02142, Cambridge, Massachusetts, United States of America (US)
From:
03/06/2016
Name:
Alcafleu Management GmbH & Co. KG
Address:
Lilienthalstrasse 4, 12529 Schönefeld OT Waltersdorf, Germany (DE)
Agent
Name:
ir. H.A. Witmans c.s.
From:
03/06/2016
Address:
V.O.
Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
43/20
Publication date:
21/10/2020
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
23/16
Publication date:
10/06/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
21/10/2020
Outgoing Correspondence
Decision refusal
2
PDF
/9/3/1/2/6/0800062139/docs/300816_11_373615l527a.pdf
13/07/2020
Outgoing Correspondence
Letter to applicant
2
PDF
/9/3/1/2/6/0800062139/docs/300816_2_353798l173.pdf
14/10/2016
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/9/3/1/2/6/0800062139/docs/300816_1_incomingcorrespondencepaper20161017030148231.pdf
14/10/2016
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/9/3/1/2/6/0800062139/docs/300816_3_incomingcorrespondencepaper20161017030148161.pdf
13/10/2016
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/9/3/1/2/6/0800062139/docs/300816_9_incomingcorrespondencepaper20161014031428956.pdf
14/07/2016
Outgoing Correspondence
Outgoing Letter
16
PDF
/9/3/1/2/6/0800062139/docs/300816_8_outgoingcorrespondence20200415095841417.pdf
07/06/2016
Outgoing Correspondence
Outgoing Letter
1
PDF
/9/3/1/2/6/0800062139/docs/300816_4_60659l174.pdf
01/06/2016
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/9/3/1/2/6/0800062139/docs/300816_0_incomingcorrespondencepaper20160603031039086.pdf
01/06/2016
SPC Documents
Annex SPC
4
PDF
/9/3/1/2/6/0800062139/docs/300816_5_supplprotectioncertificate20210330050856967.pdf
01/06/2016
Application Form
First filed application form
3
PDF
/9/3/1/2/6/0800062139/docs/300816_6_applicationform20160603031038983.pdf
01/06/2016
SPC Documents
Annex SPC
18
PDF
/9/3/1/2/6/0800062139/docs/300816_7_supplprotectioncertificate20210330050857052.pdf
01/06/2016
SPC Documents
Summary of the characteristics of the product
20
PDF
/9/3/1/2/6/0800062139/docs/300816_10_supplprotectioncertificate20210330050856885.pdf
01/06/2016
SPC Documents
Marketing Authorization SPC
3
PDF
/9/3/1/2/6/0800062139/docs/300816_12_supplprotectioncertificate20160603031039149.pdf